199 related articles for article (PubMed ID: 35879762)
1. CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma.
Wang F; Zhao F; Zhang L; Xiong L; Mao Q; Liu Y; Qiu X; Wang X; Shui L; Chen X; Ren K; Shui P; Zhang Q; Deng Y; Li W; Xie X; Wu D; Li T; Lang J; Liu L; Chen H; Xu J; Bai S; Li Z; Yue Q; Chen N; Zhou B; Yi C; Wei Y; Fu Y; Luo Y; Gou Q; Liu L; Liu Y; Kang J; Wang J; Jing D; Zhang F; Yang X; Li X; Jiang T; Zhang Z; Zhou Y; Yi J
Mol Cancer; 2022 Jul; 21(1):153. PubMed ID: 35879762
[TBL] [Abstract][Full Text] [Related]
2. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
3. MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway.
Ren J; Zheng S; Zhang L; Liu J; Cao H; Wu S; Xu Y; Sun J
Cancer Med; 2023 May; 12(10):11624-11640. PubMed ID: 36999945
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
5. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
6. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
7. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
8. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
9. CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas.
Li JW; Huang QR; Mo LG
Medicine (Baltimore); 2022 Aug; 101(33):e30044. PubMed ID: 35984129
[TBL] [Abstract][Full Text] [Related]
10.
Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
Front Immunol; 2022; 13():974346. PubMed ID: 36275718
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Biomarker KIF18A and Its Correlations With Immune Infiltrates and Mitosis in Glioma.
Tao BY; Liu YY; Liu HY; Zhang ZH; Guan YQ; Wang H; Shi Y; Zhang J
Front Genet; 2022; 13():852049. PubMed ID: 35591854
[No Abstract] [Full Text] [Related]
12. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
13. Cullin-7 (CUL7) is overexpressed in glioma cells and promotes tumorigenesis via NF-κB activation.
Xu J; Zhang Z; Qian M; Wang S; Qiu W; Chen Z; Sun Z; Xiong Y; Wang C; Sun X; Zhao R; Xue H; Li G
J Exp Clin Cancer Res; 2020 Apr; 39(1):59. PubMed ID: 32252802
[TBL] [Abstract][Full Text] [Related]
14. A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2.
Wu X; Chen H; You C; Peng Z
Hereditas; 2023 May; 160(1):21. PubMed ID: 37170390
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics analysis of LMAN1 expression, clinical characteristics, and its effects on cell proliferation and invasion in glioma.
Du Q; Lin Y; Zhang W; He F; Xu Y; Chen Z
Brain Res; 2022 Aug; 1789():147952. PubMed ID: 35623391
[TBL] [Abstract][Full Text] [Related]
16. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.
Zhao H; Zhou X; Yuan G; Hou Z; Sun H; Zhai N; Huang B; Li X
Clin Transl Oncol; 2021 Mar; 23(3):565-571. PubMed ID: 32661826
[TBL] [Abstract][Full Text] [Related]
17. High LYRM4-AS1 predicts poor prognosis in patients with glioma and correlates with immune infiltration.
Wang HY; Xie Y; Du H; Luo B; Li Z
PeerJ; 2023; 11():e16104. PubMed ID: 37810780
[TBL] [Abstract][Full Text] [Related]
18. KDELR1 Is an Independent Prognostic Predictor and Correlates With Immunity in Glioma.
Yuan Y; Yang B; Qi Z; Han Z; Cai J; Song J
Front Oncol; 2022; 12():783721. PubMed ID: 35814367
[TBL] [Abstract][Full Text] [Related]
19.
Chen Z; Cui S; Dai Y; Lu C; Zhang H; Zhao W; Yan H; Zhang Y
Oxid Med Cell Longev; 2022; 2022():7595230. PubMed ID: 36193074
[TBL] [Abstract][Full Text] [Related]
20. ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
Ming Y; Luo C; Ji B; Cheng J
BMC Cancer; 2023 Oct; 23(1):937. PubMed ID: 37789267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
